2
April 2024
Argent BioPharma
Ltd
Change of name to Argent
BioPharma Limited
Argent BioPharma Ltd (Argent BioPharma or the Company), an innovative drug discovery
company within the biopharmaceutical sector, has formally changed
its name from MGC Pharmaceuticals Limited to Argent BioPharma
Limited as approved by shareholders at a General Meeting held 18
March 2024.
Change of name to Argent BioPharma Ltd
The name change has been processed
by the Australian Securities and Investments Commission and will
take effect on the ASX from commencement of trading on Wednesday, 3 April 2024. The Company's
ASX code will migrate to RGT.
The name change will have a delayed
effective date in the UK due to additional regulatory requirements
that can only be met after the effective date on the ASX, the
anticipated effective date of change for the UK is 10 April 2024. The Company's new
ISIN and TIDM are AU0000326647 and RGT respectively.
The Company's website address is
now www.argentbiopharma.com.
Shareholders should note that their
shareholdings will be unaffected by the change of name. Existing
share certificates should be retained as they will remain valid for
all purposes and no new share certificates will be
issued.
Company Overview
In a notable milestone signalling the conclusion of its restructuring
process, supported by a substantial injection of capital and a
comprehensive operational transformation, Argent BioPharma is set
to position itself as a significant player in pioneering drug
discovery within the biopharmaceutical sector. With dual listings
on both the London Stock Exchange and the Australian Stock
Exchange, Argent BioPharma is poised to make a considerable impact
in advancing medical treatment accessibility, harnessing
sophisticated methodologies in PolyPharmacology and
Nanotechnology.
As a key pillar of Argent
BioPharma's philosophy, the Company embraces PolyPharmacology, an
innovative methodology focused on crafting and implementing
therapeutics to influence numerous molecular targets
simultaneously. This approach plays a pivotal role in effectively
tackling the intricacies of multifaceted diseases, thereby
establishing a pioneering benchmark in both drug development and
therapeutic effectiveness.
Operational Highlights
Argent BioPharma is positioned to
generate revenue through its Investigational Medicinal Products
(IMPs), CannEpil® and CimetrA®, which are accessible to patients
through early access schemes in key markets including the UK, USA,
and Europe. These initiatives are further supported by real-world
data obtained from early access treatments, offering valuable
insights into safety and efficacy that bolster clinical trial
outcomes.
Argent BioPharma's European research
hub is a key asset, playing a crucial role across the drug
development continuum from conceptualisation to commercialisation.
The hub operates from two distinct manufacturing facilities; one
dedicated to clinical trials and early access programmes; and the
other geared towards large-scale commercial production. Argent
BioPharma adheres rigorously to stringent EU GMP and GDP
guidelines.
Product Portfolio
Argent BioPharma places special
emphasis on its product range targeting immunology and neurology,
utilising PolyPharmacology to innovate novel treatments. Committed
to addressing unmet medical needs, the Company aims to introduce
new treatment every four years. Key products include CannEpil® for
refractory epilepsy and cerebral palsy, CimetrA® for acute lung
injury and ARDS, and CogniCann® for enhancing the quality of life
in dementia and Alzheimer's patients, with additional treatments in
development.
Roby Zomer, Managing Director and CEO of Argent BioPharma,
commented: "As Argent BioPharma
emerges from MGC Pharma, it is well positioned in the new era in
biopharmaceuticals, committed to providing accessible and impactful
healthcare solutions on a global scale. This rebranding signifies
our commitment to innovation and advancement in the
biopharmaceutical landscape. We are excited to leverage our
expertise in PolyPharmacology and Nanotechnology to pioneer
ground-breaking treatments, addressing unmet medical needs and
driving positive change in global healthcare."
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About Argent
BioPharma
Argent BioPharma is dedicated to
meeting unmet medical needs by combining PolyPharmacology and
Nanotechnology, aspiring to be a renowned global leader in the
biopharmaceutical sector. Our mission centres on researching and
developing ground-breaking treatments for worldwide health issues,
guided by strategic principles such as pioneering life science
advancements, ensuring global access, fostering continuous
innovation, and striving for industry leadership.